Country for PR: China
Contributor: Xinhua News Agency
Tuesday, February 09 2021 - 13:50
AsiaNet
Experiment showed that Jemincare's neutralizing antibody JMB2002 would likely keep the potency against the South African mutant
SHANGHAI, Feb. 9, 2021 /Xinhua-AsiaNet/--

On February 7, 2021, scientists from Jemincare Shanghai Research Institute 
published a preprint paper on BioRxiv, the paper entitled "A human antibody 
with blocking activity to RBD proteins of multiple SARS-CoV-2 variants 
including B.1.351 showed potent prophylactic and therapeutic efficacy against 
SARS-CoV-2 in rhesus macaques", which states that Jemincare's neutralizing 
antibody JMB2002, now in a phase I clinical trial, showed broad-spectrum in 
vitro blocking activity against the hACE2 binding to the RBD/S protein of 
multiple SARS-CoV-2 variants including the South African mutant (B.1.351).

Recent papers reported that a new variant of SARS-CoV-2 in South Africa, has 
emerged in many countries around the world, with much more resistant to 
neutralization by vaccine sera, it has caused the concern of epidemiologists.

The preprint paper reported that JMB2002 showed 6.8-fold higher binding 
affinity to SARS-CoV-2 S1 mutant protein of South African mutant B.1.351. 
compared to that of S1 prototype. Although, the blocking potency of JMB2002 has 
2.8-fold decreased, but still 12-fold higher than that of hACE2-Fc against the 
South African mutant, it indicated that JMB2002 would likely keep the 
neutralize potency against the South Africa mutant.

JMB2002, an anti SARS-CoV-2 neutralizing antibody, was independently developed 
by Jemincare Research Institute and started the phase I clinical trial last 
month. Preclinical data indicated that JMB2002 can precisely occupy the key 
epitope of the receptor binding domain (RBD) on the S1 subunit of the 
SARS-CoV-2 with human angiotensin-converting enzyme II (hACE2) binding 
interface, and has strong binding and blocking activities to the spike 
glycoproteins of mutant viruses.

The results from China indicate that prophylactic and therapeutic intervention 
of SARS-CoV-2 utilizing JMB2002 would likely slow down the transmission of 
currently emerged SARS-CoV-2 variants and lead to more efficient control of the 
COVID-19 pandemic.

For more information, please visit: 
https://www.biorxiv.org/content/10.1101/2021.02.07.429299v2

Source: Jemincare

Image Attachments Links:

   Link: http://asianetnews.net/view-attachment?attach-id=384026

   Caption: The preprint paper on BioRxiv

Translations

Russian

French

German